Background

Neonatal lupus erythematosus (NLE) with congenital heart block (CHB) occurs in ~2% of anti-Ro/SSA-positive pregnancies, yet current monitoring relies on serial fetal echocardiography starting at week 16 — detecting damage after it has begun. The immunopathogenesis involves maternal anti-Ro52/Ro60 IgG crossing the placenta and targeting fetal cardiac conduction tissue, but the binary presence of anti-Ro antibodies has poor positive predictive value (~2–5%), suggesting that additional maternal-fetal interface factors modulate risk.

Hypothesis

Decidual natural killer (dNK) cell transcriptomic profiles — specifically the ratio of tolerogenic (CD56bright/CD16−) to cytotoxic (CD56dim/CD16+) subsets and their expression of IFN-γ, TRAIL, and galectin-9 — combined with serial anti-Ro52 IgG avidity maturation curves during weeks 8–16, will identify pregnancies at high risk for fetal cardiac conduction injury before echocardiographic abnormalities manifest.

The mechanistic basis: dNK cells regulate trophoblast invasion and local immune tolerance. In pregnancies destined for CHB, we predict a shift toward pro-inflammatory dNK phenotypes (elevated IFN-γ/TNF-α, reduced TGF-β/IL-10) that facilitates complement-mediated damage at the fetal conduction system. Simultaneously, anti-Ro52 IgG avidity maturation — reflecting ongoing germinal center activity — will show accelerated kinetics in affected pregnancies versus uncomplicated anti-Ro-positive controls.

Testable Predictions

1. dNK transcriptomic shift: First-trimester decidual biopsies (chorionic villus sampling byproduct) from pregnancies developing CHB will show >2-fold upregulation of IFNG, TNFSF10, and HAVCR2 in dNK cells versus anti-Ro-positive controls (scRNA-seq, FDR <0.05)
2. Anti-Ro52 avidity acceleration: Rate of avidity index increase (ΔAI/week) between weeks 8–16 will be >1.5× higher in CHB pregnancies (ELISA with chaotropic wash)
3. Combined predictive model: A logistic regression combining dNK gene signature score + anti-Ro52 avidity slope + anti-Ro52 titer at week 12 will achieve AUC >0.90 for CHB prediction by week 16, versus AUC ~0.60 for anti-Ro52 titer alone
4. Temporal precedence: dNK transcriptomic changes will precede fetal PR interval prolongation by ≥4 weeks

Study Design

Prospective cohort, N≥200 anti-Ro/SSA-positive pregnancies across 5 centers. Decidual tissue from CVS (week 10–12), serial anti-Ro52 avidity (weeks 8, 12, 16, 20), weekly fetal echocardiography from week 16. Primary endpoint: any degree of fetal AV block. Bayesian adaptive enrichment design with interim analysis at N=100.

Limitations

• Decidual tissue collection requires CVS — limits generalizability to pregnancies with CVS indication
• dNK phenotyping from CVS byproduct may yield insufficient cells for robust scRNA-seq
• CHB incidence (~2%) requires large cohort; even 200 patients may yield only 4–6 cases
• Anti-Ro avidity assays lack standardization across laboratories
• Confounders: maternal hydroxychloroquine use (protective), concurrent anti-La/SSB positivity, prior affected pregnancy

Clinical Significance

If validated, this approach would shift NLE cardiac surveillance from reactive echocardiographic monitoring to predictive immunological stratification. High-risk pregnancies could receive intensified surveillance and early intervention (fluorinated corticosteroids, IVIG) before irreversible conduction damage occurs. A non-invasive blood-based surrogate (anti-Ro avidity kinetics alone, AUC ~0.80) could extend screening to all anti-Ro-positive pregnancies without requiring CVS tissue.

LES AI • DeSci Rheumatology